Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XORTX Therapeutics Inc. filings document foreign issuer reports for a clinical-stage pharmaceutical company developing therapies for gout and progressive kidney disease. The records describe its XRx-026, XRx-008, XRx-101, XRx-225 and VB4-P5 programs, including disease focus, development stage and acquired intellectual property, regulatory documentation and manufacturing data for the VB4-P5 kidney anti-fibrotic asset.
The company’s Form 6-K disclosures also cover capital structure and exchange-listing matters, including a completed share consolidation, Nasdaq continued-listing compliance, preliminary stockholders’ equity information, acquisition consideration involving common shares and pre-funded warrants, and shareholder meeting results. Governance filings report director elections, auditor appointments, stock option plan approval and related voting outcomes.
XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange while maintaining its listing on Nasdaq. The board-approved decision follows a review that found the costs, administrative burden, and differing regulatory environments of a dual listing were not justified.
The company expects the delisting to eliminate duplicative exchange fees, reduce legal and accounting expenses, and simplify regulatory requirements, allowing management to focus more on advancing its XRx-026 gout program and other kidney disease therapies. Shareholders, including those in Canada, will continue to have full trading access to XORTX shares on Nasdaq, and no shareholder action is required.
XORTX Therapeutics Inc. reports the closing of a US$5 million public offering of 2,659,574 common shares or pre-funded warrant equivalents at US$1.88 each. The company issued 183,577 common shares and 2,475,997 pre-funded warrants, each exercisable for one share at US$0.0001.
Gross proceeds were US$5 million before fees, including a US$200,000 (4%) cash commission to E.F. Hutton & Co. XORTX plans to use the net proceeds for working capital and general corporate purposes, including investor relations activities. A portion of US$2.5 million will be paid to IR Agency LLC for marketing and advertising services. The closing remains subject to final TSX Venture Exchange approval.
XORTX Therapeutics Inc. reports Q1 2026 interim results showing a net and comprehensive loss of $808,472 and no product revenue. Operating cash outflow was $574,265, leaving cash of $250,275 and a working capital deficit of $116,572. Management discloses a material uncertainty about the company’s ability to continue as a going concern.
To strengthen its pipeline, XORTX completed the acquisition of the VB4-P5 renal anti-fibrotic program from Vectus for equity and pre-funded warrants valued at $3.0 million. It also initiated a public offering of 2,659,574 common shares or pre-funded warrants with gross proceeds of up to $5 million, currently held in escrow pending TSX Venture Exchange approval.
During the quarter, expenses were driven by professional fees of $312,379, consulting and wages of $195,380, and investor relations of $94,973, while research and development spending declined to $33,113. Shareholders approved a 1‑for‑5 share consolidation completed on April 6, 2026, which helped the company regain compliance with Nasdaq’s minimum bid price requirement.
XORTX Therapeutics is offering 183,577 common shares and Pre-Funded Warrants to purchase up to 2,475,997 common shares pursuant to this prospectus. The offering was conducted on a reasonable best efforts basis and terminated on May 13, 2026 upon entry into a placement agent agreement.
The company priced Shares at $1.88 per Share and Pre-Funded Warrants at $1.8799. Net proceeds are expected to be approximately $4.7 million (after fees), intended for R&D, working capital and investor relations including up to $2 million to IR Agency LLC. The offering assumes shareholder and exchange actions already completed, including a 5:1 share consolidation and the April 13, 2026 Vectus asset acquisition.
XORTX Therapeutics Inc. has priced a public offering of 2,659,574 common shares or pre-funded warrant equivalents at US$1.88 per share for gross proceeds of US$5 million before fees and expenses. The pre-funded warrants are immediately exercisable at US$0.0001 per share and terminate once fully exercised.
The offering is being made under an effective Form F-1 registration statement that was declared effective by the U.S. Securities and Exchange Commission on May 13, 2026 and is expected to close on or about May 15, 2026, subject to customary closing conditions and TSX Venture Exchange approval. E.F. Hutton & Co. is acting as exclusive placement agent.
XORTX Therapeutics Inc. estimates its stockholders’ equity at approximately $4.1 million as of this report, which it believes is above the minimum required for continued listing on the Nasdaq Capital Market. This estimate reflects its anticipated stockholders’ equity as of March 31, 2026, the April 13, 2026 closing of its acquisition of Vectus Biosystems Limited’s VB4-P5 asset, and estimated results for the first quarter and early second quarter of 2026.
The company stresses that these figures are preliminary, unaudited and subject to change once full financial closing and review are completed. It cautions that actual results for the three months ended March 31, 2026 could differ materially and that investors should not place undue reliance on this early financial information or forward-looking statements.
XORTX Therapeutics Inc. is offering up to 1,805,054 common shares (or, in certain cases, Pre-Funded Warrants exercisable into the same number of shares) in a "reasonable best efforts" placement at an assumed price of $2.77 per share. The prospectus explains that Pre-Funded Warrants will be issued to purchasers who would otherwise exceed 4.99% (or electively 9.99%) beneficial ownership limits; each Pre-Funded Warrant has an exercise price of $0.0001 and is immediately exercisable. The company expects approximately $4.7 million of net proceeds assuming the assumed price and no Pre-Funded Warrants are sold; uses include R&D, working capital and up to $2.0 million for investor relations services. The filing also describes a recent asset acquisition (VB4-P5), a 5-for-1 share consolidation, regained Nasdaq compliance, and pro forma capitalization and dilution tables.
XORTX Therapeutics Inc. filed a Post-Effective Amendment to its Form F-1 registering up to 2,202,643 common shares or up to 2,202,643 pre-funded warrants, using an assumed offering price of $2.27 per share. The company estimates approximately $4.7 million of net proceeds (assuming sale of all Shares and no pre-funded warrants), which it expects to use for research and development, working capital and general corporate purposes, including up to $2.0 million to IR Agency LLC for investor relations activities. The filing notes a recent 5-for-1 share consolidation (effective April 6, 2026) and the April 13, 2026 acquisition of Vectus assets for $3.0 million paid via 154,544 common shares and 692,150 pre-funded warrants.
XORTX Therapeutics is offering up to 2,202,643 common shares (or up to 2,202,643 pre-funded warrants in lieu of shares) in a primary offering under a post-effective amendment to its Form F-1. The prospectus uses an assumed public offering price of $2.27 per share and states the company expects approximately $4.7 million of net proceeds based on that price and assuming no sale of pre-funded warrants. The offering includes ownership limits that permit certain purchasers to elect pre-funded warrants to avoid exceeding 4.99% (or, if elected, 9.99%) beneficial ownership thresholds. Shares outstanding were 2,239,137 as of April 17, 2026. The Placement Agent is E.F. Hutton & Co. and the placement will be conducted on a reasonable best efforts basis.